Fidaxomicin: novel antibiotic for Clostridium difficile infection

Fidaxomicin (Dificlir) is a new antibiotic licensed for the treatment of C. difficile infection in adults. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse events and Professor Mark Wilcox discusses its place in treatment.


Add yours ↓
Web design and marketing agency Leamington Spa